SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-061553
Filing Date
2023-11-09
Accepted
2023-11-09 08:02:36
Documents
69
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20230930.htm   iXBRL 10-Q 2767269
2 EX-31.1 acrv-ex31_1.htm EX-31.1 17044
3 EX-31.2 acrv-ex31_2.htm EX-31.2 17023
4 EX-32.1 acrv-ex32_1.htm EX-32.1 11412
5 EX-32.2 acrv-ex32_2.htm EX-32.2 11395
  Complete submission text file 0000950170-23-061553.txt   9489691

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acrv-20230930.xsd EX-101.SCH 56301
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acrv-20230930_pre.xml EX-101.PRE 385631
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT acrv-20230930_cal.xml EX-101.CAL 52556
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acrv-20230930_lab.xml EX-101.LAB 481898
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acrv-20230930_def.xml EX-101.DEF 249575
63 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20230930_htm.xml XML 1616911
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 231390149
SIC: 2834 Pharmaceutical Preparations